Welcome to our dedicated page for Immunovant news (Ticker: IMVT), a resource for investors and traders seeking the latest updates and insights on Immunovant stock.
Immunovant, Inc. reports recurring developments from a clinical-stage immunology business focused on anti-FcRn therapies for autoimmune diseases. Its news flow centers on IMVT-1402, a potential neonatal Fc receptor inhibitor, and batoclimab, with updates across Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus and thyroid eye disease.
Company updates also cover quarterly operating results, research and development spending, trial design and clinical-study results, safety observations, cash runway, financing activity and shareholder voting matters. Because Immunovant operates in a single research, development and manufacturing segment, recurring disclosures are closely tied to clinical execution, product-candidate manufacturing and capital resources for autoimmune disease programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Immunovant (Nasdaq: IMVT) reported a net loss of $63.2 million, or $0.49 per share, for Q3 FY2022, compared to a loss of $41.4 million, or $0.36 per share, in Q3 FY2021. Cash reserves stood at approximately $433 million, expected to fund operations through 2025. The company initiated a Phase 3 trial for batoclimab in thyroid eye disease and a pivotal Phase 2b trial in chronic inflammatory demyelinating polyneuropathy. A Phase 1 trial for IMVT-1402 is expected to begin in early 2023. Investors anticipate multiple data readouts starting mid-2023, potentially enhancing the company’s position in autoimmune therapies.